RxDoctor Payments Data

Vidyadhar Gandra, MD

Cardiovascular Disease · Crown Point, INNPI 1770580789

Payments from drug & device makers

$1,017in general payments, 2019–2025

Across 52 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$365
  • Johnson & Johnson$232
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$126
  • Amgen$67
  • Pfizer$58
  • Lundbeck LLC$36
  • plus $134 from 6 others

What the payments were for

  • Food & beverage$1,017100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,017 in reported general payments places this provider in the 30th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$57,055
Medicare patients
295
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$216,858
XareltoRivaroxaban45$57,872
EntrestoSacubitril/Valsartan29$46,616
Repatha SureclickEvolocumab42$33,933
JardianceEmpagliflozin23$26,715
Metoprolol Succinate359$4,764
Atorvastatin Calcium294$2,793
Rosuvastatin Calcium185$1,598
ClopidogrelClopidogrel Bisulfate86$1,499
Ezetimibe64$1,490
Losartan Potassium140$1,265
Spironolactone138$1,147
Amlodipine Besylate188$1,101
Furosemide152$1,091
Diltiazem 24hr Er (Cd)Diltiazem Hcl53$1,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$216,858166 claims
Johnson & JohnsonXarelto$232$57,87245 claims
NovartisEntresto$365$46,61629 claims
Boehringer IngelheimJardiance$29$26,71523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Crown Point

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →